On the 3rd of April, investors will gather together to explore an exclusive investment opportunity in cancer diagnostics.
The company has developed an advanced liquid biopsy technology that revolutionizes cancer detection. Tech know-how: non-invasive approach detects, isolates, and characterizes all circulating tumor cells (CTCs) from blood samples with unprecedented sensitivity. It is capable of identifying 1 CTC in 40 billion cells (8ml blood)! 

This advancement surpasses both competitor technologies and routine tissue-based methods, enabling highly precise personalized cancer care, while reducing timelines and costs. The technology is now almost market ready. 

During the Atrium, the project will be presented to a interested investors and, after listening to the presentation, investors will work together to provide the project with their valuable feedback and advice, a development solution, all kinds of support, and, of course, monetary resources to help close the round and ensure its development in the best possible way. After that a round of one-to-one meetings with investors follows.